Jiawei Duhuo Jisheng Mixture Alleviates Knee Osteoarthritis via Inhibition of TLR4/MyD88/NF‐κB Signaling and Is Associated With Gut Microbiota Alterations
Immunity, Inflammation and Disease · 2026-11 · 14 (11)
DOI: 10.1002/iid3.70586 ↗Abstract
ABSTRACT Objective To evaluate the chondroprotective effects of Jiawei Duhuo Jisheng Mixture (JDJM) in KOA and to determine whether JDJM modulates the TLR4/MyD88/NF‐κB axis and is associated with gut microbiota alterations. Methods A KOA model was established in New Zealand rabbits using a modified Videman method ( n = 36). Animals were assigned to a blank control group ( n = 6) or underwent modeling and were then randomized into the model, JDJM low‐, medium‐, or high‐dose, and positive control groups ( n = 6/group). Treatments were administered intragastrically for 6 weeks. Cartilage histopathology, evaluated by H&E staining and OARSI scoring, constituted the primary histopathological assessment, with the OARSI score serving as the quantitative primary endpoint. Secondary mechanistic outcomes included serum inflammatory cytokines and TLR4/MyD88/NF‐κB‐related measures in cartilage tissue, including NF‐κB p65 nuclear translocation. In vitro, primary rabbit chondrocytes were exposed to IL‐1β–induced inflammatory stimulation to provide supportive mechanistic evidence through assessment of cell viability, apoptosis, inflammatory mediators, and pathway‐related molecules. Molecular docking was additionally performed to explore potential interactions between identified JDJM constituents and TLR4/MD‐2, MyD88, and NF‐κB p65. Fecal 16S rRNA sequencing and related gut microbiota analyses were considered exploratory. Results Compared with the model group, JDJM attenuated cartilage histopathological damage and reduced OARSI scores, while decreasing serum levels of pro‐inflammatory cytokines (IL‐1β, IL‐6, TNF‐α, and IFN‐γ). In cartilage tissue, JDJM reduced TLR4, MyD88, and NF‐κB expression and suppressed NF‐κB p65 nuclear translocation. In vitro, JDJM increased the viability of IL‐1β–stimulated chondrocytes, reduced apoptosis, and decreased the release of inflammatory mediators. Molecular docking revealed distinct docking profiles of JDJM constituents against TLR4/MD‐2, MyD88, and NF‐κB p65. 16S rRNA sequencing indicated a shift in gut microbiota composition in the KOA model. Following JDJM treatment, microbiota composition was modulated, and several bacterial genera showed significant correlations with inflammatory markers and pathway‐related molecules. Conclusion JDJM exerted anti‐inflammatory and chondroprotective effects in in vivo KOA models and in vitro primary chondrocytes. These effects may be mediated, at least in part, by inhibition of the TLR4/MyD88/NF‐κB signaling axis. The observed microbiota changes suggest that the gut–joint axis may contribute to the overall effects, although causal relationships require further validation.
EUVIMED